>

Ian Read - Pfizer Chairman, CEO and Chairman of Executive Committee

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>PFE</div>
PFE -- USA Stock  

Trending

  Chairman
Mr. Ian C. Read is Executive Chairman of the Board of Pfizer Inc. He was Chairman of the Board and Chief Executive Officer from December 2011 to December 2018. President and Chief Executive Officer from December 2010 until December 2011. Previously, he served as Senior Vice President and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business unitsPrimary Care, Specialty Care, Oncology, Established Products and Emerging Markets. Chair of the Pfizer Foundation. Director of KimberlyClark Corporationrationration.Mr. Read brings over 35 years of business, operating and leadership experience to the Board. His extensive knowledge of the biopharmaceutical industry in general, and Pfizers worldwide biopharmaceutical business in particular, provides crucial insight to our Board on the companys strategic planning and operations. Mr. Read provides advice and counsel to management and the Board, and the combination of his knowledge of the business and his leadership skills makes his role as Executive Chairman optimal at this time. In addition, his experience as a member of another public company board provides him with an enhanced perspective on issues applicable to public companies.
Age: 64  Chairman Since 2018      
212 733-2323  www.pfizer.com

Ian Read Latest Insider Activity

Management Efficiency

The company has Return on Asset of 0.09 % which means that on every $100 spent on asset it made $0.09 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.0 % .
The company has 47.96 B in debt with debt to equity (D/E) ratio of 80.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Pfizer has Current Ratio of 1.44 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Alex KrauerNovartis AG
N/A
Sandra PetersonJohnson Johnson
2017
Joaquin DuatoJohnson Johnson
2018
Ulrich LehnerNovartis AG
2006
Leif JohanssonAstrazeneca PLC
2012
John MartinGilead Sciences
N/A
Lamberto AndreottiBristol Myers Squibb Company
2015
Paul BisaroAllergan Plc
2016
Daniel VasellaNovartis AG
N/A
Alex GorskyJohnson Johnson
2012
Ashley McEvoyJohnson Johnson
2018
Kenneth FrazierMerck Company
2011
Moncef SlaouiGlaxoSmithKline PLC
2014
Jorge MesquitaJohnson Johnson
2016
John LechleiterEli Lilly And Company
2016
Enrico VanniNovartis AG
2013
Daniel ODayGilead Sciences
2019
Jennifer TaubertJohnson Johnson
2018
Joerg ReinhardtNovartis AG
2013
Thibaut MongonJohnson Johnson
2018
Paulus StoffelsJohnson Johnson
2018

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 88300 people.Pfizer (PFE) is traded on BATS Exchange in USA. It is located in 235 East 42nd Street, New York, NY 10017, United States and employs 88,300 people. Pfizer is listed under Pharmaceutical Products category by Fama And French industry classification.

Pfizer Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela HwangView
Jennifer Damico, Senior Vice President Principal Accounting Officer, ControllerView
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global SupplyView
Douglas Lankler, Executive Vice President General CounselView
Dawn Rogers, Chief Human Resource Officer, Executive Vice PresidentView
Helen Hobbs, Independent DirectorView
Shantanu Narayen, Lead Independent DirectorView
James Smith, Independent DirectorView
Dennis Ausiello, Independent DirectorView
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and MedicalView
Frances Fergusson, Independent DirectorView
Stephen Sanger, Independent DirectorView
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital OfficerView
Gordon Loh, Senior Vice President Corporate AuditView
Wyllie Cornwell, Independent DirectorView
Suzanne Johnson, Independent DirectorView
Alexander Mackenzie, Executive Vice President Chief Development OfficerView
Geno Germano, Group President of Global Innovative Pharma Bus.View
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial OperationsView
Sally Susman, Chief Corporate Affairs Officer, Executive Vice PresidentView
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global SupplyView
Susan Hockfield, Independent DirectorView
Freda LewisHall, Executive Vice President Chief Medical OfficerView
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice PresidentView
Dan Littman, Independent DirectorView
Ian Read, Chairman, CEO and Chairman of Executive CommitteeView
James Kilts, Independent DirectorView
Don Cornwell, Independent DirectorView
James Quincey, Independent DirectorView
Charles Hill, Executive Vice President - Worldwide Human ResourcesView
Joseph Echevarria, Independent DirectorView
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare BusinessView
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global SupplyView
Angela Hwang, Group President, Pfizer Biopharmaceuticals GroupView
Scott Gottlieb, Independent DirectorView
Ronald Blaylock, Independent DirectorView
Kathrin Jansen, Senior Vice President - Vaccine Research & DevelopmentView
Michael Goettler, Group President - Pfizer UpjohnView

Stock Performance Indicators

Current Sentiment - PFE

Pfizer Investor Sentiment

Predominant part of Macroaxis users are at this time bullish on Pfizer. What is your perspective on investing in Pfizer? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

BXRX   
Purchased over 100 shares of
few hours ago
Traded for 2.34
WD   
Purchased over 70 shares of
few hours ago
Traded for 42.57
TWTR   
Purchased over 100 shares of
few hours ago
Traded for 25.97
V   
Purchased few shares of
few hours ago
Traded for 161.56
VMW   
Purchased over 20 shares of
few hours ago
Traded for 115.74
Please check Your Equity Center. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page